,30,31 Clinically applied immune checkpoint inhibitors (ICIs), such as anti-PD-L1 antibody and anti-PD1 antibody, prevent tumor cell immune escape by blocking immune checkpoints.32 This evidence concerns the gene CD274 and neoplasm.